Meitheal FDA Tuesday, June 29, 2021 0.00 Neutral

FDA Approves DAPTOMYCIN — Meitheal Pharmaceuticals Inc.

Meitheal Pharmaceuticals Inc. secured FDA approval for its intravenous Daptomycin, positioning the company to capitalize on the high-value antibiotic market and potentially capture significant share as a generic alternative.

View original filing at SEC.gov →
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.

Get real-time financial news in your trading bot or app

GET FREE KEY — 10,000 calls/day